Eli Lilly News

Irma Sotelo-New, a scientist at Isis, worked near a condensing unit in the lab. - Isis Pharmaceuticals is a two-decade-old biotech company in Carlsbad that is on the verge of profitability.

SHADELAND Officials with Eli Lilly and Co. on Tuesday informed employees at Tippecanoe Laboratories that a decision on the future of the facility won't be made by the end of July.

Eli Lilly & Co.a s tumor-fighter Erbitux doesna t prolong lung cancer patientsa lives enough to justify its $80,000 cost, U.S. scientists said in commentary published today.

Yes No BCBR Article Level 3 expands ImClone contract By Business Report Staff June 29, 2009 -- BROOMFIELD - Level 3 Communications Inc.

Bart Peterson didn't know when he sat next to Eli Lilly's John Lechleiter in March that he would be working for the chief executive in June.

U.S. stocks fell as the highest American savings rate in 15 years spurred concern that spending will slow, while falling oil drove down energy producers.

UTEK Corporation , a leading innovation services company, and The wRatings Corporation, an independent stock research firm, announced today the results of their annual Most Competitive Companies in Health Care Study.

Jun 25, 2009 - Saint Joseph's Translational Research Institute , the research division of Saint Joseph's Health System, announced today that Jai Pal Singh, Ph.D., will join SJTRI as chief scientific officer.

An index measuring the expectations of 95 CEOs from among the nation's largest companies showed an improved outlook from last quarter's record low, but many still expect declines in sales, jobs and capital spending.

An antitrust inquiry into Merck & Co.'s planned purchase of Schering-Plough Corp.

President Barack Obama today welcomed the pharmaceutical industry's agreement to help close a gap in Medicare's drug coverage, calling the pact a step forward in the push for an overhaul of the nation's health care system.

Eli Lilly won the prize for last week's most innovative business plan. The company is transforming itself from a fully integrated big pharma to a partnership model, which it calls a Fully Integrated Pharmaceutical Network .

WASHINGTON -- President Barack Obama and Democratic lawmakers scouring for money to reduce the cost of comprehensive health-reform legislation cheered news Saturday that drug makers have agreed to squeeze $80 billion out of revenue during the next decade.

Eli Lilly and Company engages in the discovery, development, manufacture, and sale of pharmaceutical products in the United States, Puerto Rico, and internationally.

Drugmakers agreed to spend as much as $80 billion over 10 years to make it easier for elderly Americans to afford medicine, a move President Barack Obama hailed as a oea turning pointa in his effort to overhaul the nationa s health-care system.

If you invest with your heart, then MannKind is a great story. Propelled by the will and the bankroll of billionaire chairman and CEO Alfred Mann, this tiny company is striving to make an inhaled form of insulin.

Below are seven companies from the BioMedReports.com FDA Calendar database of over 200 entries, which have pending new drug decision at the FDA combined with a stock price that is below its 200-day moving average .

Eli Lilly - Challenges Remain 0 ) LLY Share Eli Lilly and Company turned in a solid year in 2007 and again in 2008.

We posted a number of times about questionable practices Eli Lilly used to market its atypical anti-psychotic drug Zyprexa .

MacroGenics, Inc. and Eli Lilly and Company announced that the PROTEGE trial achieved its targeted patient enrollment.